Market capitalization | $235.25m |
Enterprise Value | $477.07m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | negative |
Turnover (TTM) Turnover | $0.00 |
EBIT (operating result TTM) EBIT | $-167.85m |
Free cash flow (TTM) Free cash flow | $-142.08m |
Cash position | $230.33m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
2 Analysts have issued a Omeros Corporation forecast:
2 Analysts have issued a Omeros Corporation forecast:
Dec '23 | |
Current assets | 218 218 |
Fixed assets | 160 160 |
Total assets | 378 378 |
Dec '23 | |
Equity | -25 -25 |
Debt capital | 403 403 |
Total capital | 378 378 |
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
Head office | United States |
CEO | Gregory Demopulos |
Employees | 198 |
Founded | 1994 |
Website | www.omeros.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.